Company: ENTXW
Filing Date: 2025-01-10
Form Type: 424B5
Source: 0001178913-25-000079
Chunk: 4

Company: Entera Bio Ltd.
Filing Date: 2025-01-10
Form: 424B5
Chunk 4
---
ations    | We may be a passive foreign investment company for the current or any other taxable year, which generally would result in adverse U.S. federal income tax consequences to our U.S.                                                         
 investors. See “Risk Factors” beginning on page  S-3 for further information.                                                                                                                                                              |

<div align='center'>**The number of shares to be outstanding after this offering above is based on our actual ordinary shares outstanding as of January 9, 2025 and excludes:**</div>

| • | 8,557,684 of our ordinary shares issuable upon the exercise of options outstanding as of September 30, 2024, at a weighted average exercise price of $2.40 per ordinary share; |

| • | 212,011 of our ordinary shares issuable upon the exercise of restricted shares units outstanding as of September 30, 2024; |

| • | 1,254,490 of our ordinary shares issuable upon the exercise of pre-funded warrants outstanding as of September 30, 2024; |

| • | 8,494,195 of our ordinary shares issuable upon the exercise of warrants outstanding as of September 30, 2024, at a weighted average exercise price of $1.00 per ordinary share; and |

| • | 1,826,726 of our ordinary shares reserved for future issuance under our 2018 Equity Incentive Plan as of September 30, 2024. |

S - 2 RISK FACTORS You should carefully consider the risks and uncertainties described under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 8, 2024 and in any updates to those risk factors in our Quarterly Reports on Form 10-Q or subsequent Annual Reports on Form 10-Ks and Quarterly Reports on Form 10-Q incorporated by reference herein, as well as the other information in this prospectus supplement and the accompany prospectus before making an investment in our ordinary shares. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our ordinary shares could decline and you could lose all or part of your investment. This prospectus supplement also contains forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements.” Our actual results could differ materially and adversely from those